In vivo comparison of the biological activity of topical methylprednisolone aceponate formulations using vasoconstriction assay


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Methylprednisolone aceponate (MPA) is potent (class III) topical corticosteroid widely used for the treatment of inflammatory dermatoses. It's peculiarities are exceptionally favorable safety profile, high anti-inflammatory activity and properties of prodrug - after application to the skin MPA is transformed into active metabolite methylprednisolone 17-propionate, and this process goes more intensively in the zone of inflammation thus limiting steroid effect on intact skin. After the patent expiration generic MPA drugs which didn't pass through the full cycle of clinical trials have entered some markets, in cluding Russian. Metabolic profile of these generics and it's equivalence to the original product is unknown. Objective. To assess biological activity of various drug formulations of original (Advantan®) and generic (Komfoderm®) drugs of MPA using vasoconstriction assay in the in vivo model. Methods. Recommended doses of studied formulations were applied to the skin of laboratory animals (mini-pigs), and then experimental measurements of chromometric data were performed at specific timepoints (0.5 h, 3h, 6 h, 12 h, 24 h) using chromometer FRU WR-10 (8 mm). Results. Difference in the profile of biologic activity based on vasoconstriction assay data was noticed for all tested MPA drugs, ranging in descending order for lightness parameter L: Advantan® cream - Advantan® milk - Advantan® fatty ointment - Advantan® ointment - Komfoderm® K cream - Komfoderm® ointment - Komfoderm ® M2 ointment. Conclusions. Applicability of colorimetric method for evaluation of intensity of biologic effect of glucocorticoids based on the level of lightness of skin surface confirmed. Differences for this parameter for studied drugs detected. Noticed tendency to higher activity of the original drug in comparison to the generic.

Full Text

Restricted Access

About the authors

M. S. Nesterov

Scientific Center of Biomedical Technologies of the Federal Medical and Biological Agency of Russia

Author for correspondence.
Email: mdulya@gmail.com

Head of Laboratory for Bioanalytical Research

Moscow region, Krasnogorsk district, pos. Bright mountains, Russia)

D. V. Khvostov

V.M. Gorbatov Federal Research Center for Food Systems, Russian Academy of Sciences

Email: daniil_hvostov@mail.ru

Junior Research Scientist, Laboratory of Molecular Biology and Bioinformatics

Moscow, Russia

R. A Ageldinov

Scientific Center of Biomedical Technologies of the Federal Medical and Biological Agency of Russia

Email: ageldinov@gmail.com
Research Scientist, Laboratory for Bioanalytical Research Moscow region, Krasnogorsk district, pos. Bright mountains, Russia)

References

  1. Левина Ю.Г., Алексеева А.А., Вишнева Е.А. и др. Особенности наружной терапии атопического дерматита у детей: роль метилпреднизолона ацепоната. Педиатрическая фармакология. 2014; 11(5): 52-58. doi: 10.15690/pfv11i5.1165
  2. Ruzicka T. Methylprednisolone aceponate in eczema and other inflammatory skin disorders - a clinical update.Int. J. Clin. Pract. 2006; 60(1): 85-92. doi: 10.1111/j.1368-5031.2005.00754.x.
  3. Zaumseil R.P., Fuhrmann H., Kecskes A., et al. Methylprednisolone aceponate (Advantan) - an effective topical corticoid therapy with few side effects. (In German). Jahrb. Dermatol. 1992; 3: 247-263.
  4. Fritsch P. Clinical experience with methylprednisolone aceponate (MPA) in eczema. J. Dermatolog. Treat. 1992; 3(Suppl. 2): 17-19. doi: 10.3109/09546639209092768.
  5. Luger T., Loske K.D., Elsner P., et al. Topical skin therapy with glucocorticoids-therapeutic index. (In German). J. Dtsch. Dermatol. Ges. 2004; 2(7): 629-634.
  6. Волкова Е.Н., Ланге Д.А., Родина Ю.А., Тарасова М.В. Метилпреднизолона ацепонат в комплексной терапии хронических дерматозов: анализ тактических ошибок применения. Клиническая дерматология и венерология. 2010; 5: 97-102
  7. Blume-Peytavi U., Wahn U. Optimizing the treatment of atopic dermatitis in children: a review of the benefit/risk ratio of methylprednisolone aceponate. J. Eur. Acad. Dermatol. Venereol. 2011; 25(5): 508-515. doi: 10.1111/j.1468-3083.2010.03942.x.
  8. Нестеров М.С., Хвостов Д.В., Агельдинов Р.А. Результаты сравнительного метаболического анализа наружных лекарственных препаратов метилпреднизолона ацепоната in vivo. Врач. 2021; 32 (7): 86-92. doi: 10.29296/25877305-2021-07-15
  9. Andersen P.H., Bjerring P. Noninvasive computerized analysis of skin chromophores in vivo by reflectance spectroscopy. Photodermatol Photoimmunol Photomed. 1990; 7: 249-57.
  10. Baquie M., Kasraee B. Discrimination between cutaneous pigmentation and erythema: comparison of the skin colorimeters Dermacatch and Mexameter. Skin Res. Technol. 2014; 20(2): 218-27.
  11. International Color Consortium, Specification ICC. 1:2004-10 (Profile version 4.2.0.0) Image technology colour management - architecture, profile format, and data structure. 2006.
  12. Westerhof W. CIE colorimetry. In: Serup J., Jemec G.B.E., editors. Handbook of non-invasive methods and the skin. Boca Raton: CRC Press; 1995: 385-97.
  13. Takiwaki H. Measurement of skin color: practical application and theoretical considerations. J. Med. Invest. 1998; 44: 121-6.
  14. Queille-Roussel C., Pocet M., Scaffer H. Quantification of skin colour changes induced by topical corticosteroid preparations using the Minolta Chroma Meter. Br. J. Dermatol. 1991; 124: 264-270.
  15. Dermatological and Transdermal Formulations. Edited by Kenneth A. Walters. 2002; 592 p.
  16. Guidance for Indusrty: Topical-Dermatologic Corticosteroids: in-Vivo-Bioequivalence. 1995.
  17. McKenzie A. W., Stoughton R.B. Method for comparing percutaneous absorption of steroids. Arch Dermatol. 1962; 86: 608-10.
  18. Coldman M.F., Lockerbie L., Laws E.A. The evaluation of several topical corticosteroid preparations in the blanching test. Br J Dermatol. 1971; 85: 381-387.
  19. Heseltine W.W., McGilchrist J.M., Gartside R.Comparative vasoconstrictor activities of corticosteroids applied topically. Br. J. Dermatol. 1964; 76:71-73.
  20. Clanachan I., Devitt H.G., Foreman M.I., et al. The human vasoconstrictor assay for topical steroids. J. Pharmacol. Method. 1980; 4: 209-20.
  21. FDA Guidance for industry: Draft-Topical dermatological drug products NDAs and ANDAs - in vivo bioavailability and bioequivalence. In vitro studies and associated studies. 1998.
  22. Barry B. W., Woodford R. Activity and bioavailability of topical corticosteroids: in vivo/in vitro correlations for the vasoconstrictor test. J. Clin. Pharm. 1978; 3: 43-65.
  23. Haigh J.M., Kanfer I. Assessment of topical corticosteroid preparations: the human skin blanching assay.Int. J. Pharm. 1984; 19: 245-62.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Working area of application and subsequent scotch sampling for the test drugs: view of the skin areas after application of the test drugs

Download (173KB)
Indexing metadata
3. Fig. 2. FRU WR-10 (8 mm) chromometer used to perform skin surface VSCT of mini-pigs

Download (102KB)
Indexing metadata
4. Fig. 3. Curves of dynamics of lightening of skin fragments of mini-pigs after removal of test preparations from the skin during 0-24 h (absolute values)

Download (120KB)
Indexing metadata
5. Fig. 4. Relative changes (%) in lightening of skin fragments of mini-pigs after removal of test preparations from skin for 0-24 h relative to control skin area (without preparation)

Download (117KB)
Indexing metadata

Copyright (c) 2022 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies